Navigation Links
A gene family that suppresses prostate cancer
Date:3/13/2014

ITHACA, N.Y. Cornell University researchers report they have discovered direct genetic evidence that a family of genes, called MicroRNA-34 (miR-34), are bona fide tumor suppressors.

The study is published in the journal Cell Reports, March 13.

Previous research at Cornell and elsewhere has shown that another gene, called p53, acts to positively regulate miR-34. Mutations of p53 have been implicated in half of all cancers. Interestingly, miR-34 is also frequently silenced by mechanisms other than p53 in many cancers, including those with p53 mutations.

The researchers showed in mice how interplay between genes p53 and miR-34 jointly inhibits another cancer-causing gene called MET. In absence of p53 and miR-34, MET overexpresses a receptor protein and promotes unregulated cell growth and metastasis.

This is the first time this mechanism has been proven in a mouse model, said Alexander Nikitin, a professor of pathology in Cornell's Department of Biomedical Sciences and the paper's senior author. Chieh-Yang Cheng, a graduate student in Nikitin's lab, is the paper's first author.

In a 2011 Proceedings of the National Academy of Sciences paper, Nikitin and colleagues showed that p53 and miR-34 jointly regulate MET in cell culture but it remained unknown if the same mechanism works in a mouse model of cancer (a special strain of mice used to study human disease).

The findings suggest that drug therapies that target and suppress MET could be especially successful in cancers where both p53 and miR-34 are deficient.

The researchers used mice bred to develop prostate cancer, then inactivated the p53 gene by itself, or miR-34 by itself, or both together, but only in epithelium tissue of the prostate, as global silencing of these genes may have produced misleading results.

When miR-34 genes alone were silenced in the mice, the mice developed cancer free. When p53 was silenced by itself, there were signs of precancerous lesions early in development, but no cancer by 15 months of age. When miR-34 and p53 genes were both silenced together, the researchers observed full prostate cancer in the mice.

The findings revealed that "miR-34 can be a tumor-suppressor gene, but it has to work together with p53," Nikitin said.

In mice that had both miR-34 and p53 silenced concurrently, cancerous lesions formed in a proximal part of the prostrate ducts, in a compartment known to contain prostate stem cells. The early lesions that developed when p53 was silenced alone occurred in a distal part of the ducts, away from the compartment where the stem cell pool is located. This suggested there was another mechanism involved when p53 and miR-34 were jointly silenced.

Also, the number of stem cells in mice with both p53 and miR-34 silenced increased substantially compared with control mice or mice with only miR-34 or p53 independently silenced.

"These results indicated that together miR-34 and p53 regulate the prostate stem cell compartments," said Nikitin.

This is significant, as cancer frequently develops when stem cells become unregulated and grow uncontrollably, he said.

Researchers further found that p53 and miR-34 affect stem cell growth by regulating MET expression. In absence of p53 and miR-34, MET is overexpressed, which leads to uncontrolled growth of prostate stem cells and high levels of cancer in these mice.

Future work will further examine the role of p53/miR-34/MET genes in stem cell growth and cancer. The findings have implications for many types of cancer.


'/>"/>

Contact: Joe Schwartz
Joe.Schwartz@cornell.edu
607-254-6235
Cornell University
Source:Eurekalert

Related biology news :

1. Sequencing hundreds of nuclear genes in the sunflower family now possible
2. Price Family Foundation funds research collaboration between Albert Einstein College of Medicine and University of Oklahoma
3. Price Family Foundation gift will create groundbreaking structural biology institute
4. Study of rodent family tree puts brakes on commonly held understanding of evolution
5. Crown of Venezuelan paramos: A new species from the daisy family, Coespeletia palustris
6. Population Council to present more than 40 studies at International Conference on Family Planning
7. Family Resiliency Center helps study how food-bank clients afford basic non-food items
8. Family matters: Evolutionary relationships among species of magic mushrooms shed light on fungi
9. Family tree of fish yields surprises
10. PatientStream announces the industrys first Multilingual family waiting room board
11. Family studies suggest rare genetic mutations team up to cause schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2017)...   TapImmune, Inc. (NASDAQ: ... the development of innovative peptide and gene-based immunotherapeutics ... metastatic disease, announced today it has successfully completed ... second clinical lot of TPIV 200, the company,s ... manufactured vaccine product will be used to supply ...
(Date:2/2/2017)... TOKYO , Feb. 1, 2017  Central ... innovative and meaningful advances worldwide, The Japan Prize ... Japan Prize, who have pushed the envelope in ... Information and Communication. Three scientists are being recognized ... outstanding achievements that not only contribute to the ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
Breaking Biology News(10 mins):
(Date:2/18/2017)... ... February 17, 2017 , ... A leader in science-based, ... , Nerium International is proud to introduce its Age-Defying Night Cream, NeriumAD™ Formula, ... to consumers across Hong Kong. The luxury skincare products contain innovative ingredients that ...
(Date:2/17/2017)... ... ... Academy of Model Aeronautics (AMA), the nation’s leading voice ... systems (UAS), are launching a joint program to promote safe and responsible drone ... efforts. , AMA and DJI will collaborate on other potential opportunities to mutually ...
(Date:2/16/2017)... Calif. and GREENWICH, Conn. ... a private investment firm focused on venture growth ... the promotion of Josh Richardson , M.D. ... on investments in biotechnology companies.  He is a ... played important roles in Longitude,s investments in Aimmune ...
(Date:2/16/2017)... --  Biostage, Inc. (Nasdaq: BSTG ), ... organ implants to treat cancers and other life-threatening conditions ... closing on February 15, 2017 of its previously announced ... warrants to purchase 20,000,000 shares of common stock, for ... priced at $0.40 per share of common stock, with ...
Breaking Biology Technology: